How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

445 results for

Wart Immune Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses. (PubMed)

Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses. Refractory cutaneous warts are difficult to eliminate. In situ photo-immunotherapy (ISPI) is an innovative treatment concept combining local photothermal therapy (PTT) and topical immunotherapy using imiquimod. To compare the efficacy of ISPI vs topical imiquimod alone, a prospective randomized controlled trial was performed with patients suffering from refractory (...) cutaneous warts. In both groups, approximately 50% of the skin surface containing warts was treated for 6 weeks. On the basis of topical imiquimod, ISPI includes an additional 808 nm laser irradiation. Treatment response, temperatures during irradiation and histopathologic examination were evaluated. The complete response rate in the ISPI-group (22/36, 61.1%) was significantly higher than in the imiquimod alone group (11/34, 32.4%). In the ISPI-group, the mean maximum temperature was 44.5 ± 5.1°C

2019 Journal of biophotonics

2. Wart Immune Therapy

Wart Immune Therapy Wart Immune Therapy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Wart Immune Therapy Wart Immune Therapy Aka (...) : Wart Immune Therapy , Intralesional Candida Injection From Related Chapters II. Indication s refractory to other treatments Not FDA approved (anecdotal support only) III. Preparation Killed Candida (Monilia albicans) Used in Manitou control (1:1000 solution) IV. Application Preparation Mix equal parts of 1% without Use 30 gauge needle Choose largest wart Injection Inject 0.1 cc to 0.3 cc intradermal beside wart Wart should blanche with injection V. Precautions Wear protective glasses Limit to 3

2018 FP Notebook

3. Clearance of recalcitrant warts in a patient with idiopathic immune deficiency following administration of the quadrivalent human papillomavirus vaccine. (PubMed)

Clearance of recalcitrant warts in a patient with idiopathic immune deficiency following administration of the quadrivalent human papillomavirus vaccine. Human papillomavirus (HPV)-induced cutaneous warts are potentially serious and debilitating. In immunosuppressed patients, these warts may be resistant to standard therapies. We report a case of a young patient with a primary immune deficiency whose recalcitrant cutaneous warts regressed completely following administration of a quadrivalent

2017 Clinical & Experimental Dermatology

4. Cimetidine wart therapy

wart therapy Aka: Cimetidine wart therapy From Related Chapters II. Indication Recalcitrant warts in adults in Children III. Mechanism Mild Immune enhancing effect IV. Dosing Start: 25-40 mg/kg (MAX 400 mg tid) divided bid-tid Course: Treat for 2-3 months V. Side effects Unpleasant syrup s with prolonged use VI. Efficacy: Mild effect Not nearly as pronounced as originally thought VII. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing (...) Cimetidine wart therapy Cimetidine wart therapy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Cimetidine wart therapy Cimetidine

2018 FP Notebook

5. Intralesional Injection of the Measles-Mumps-Rubella Vaccine into Resistant Palmoplantar Warts: A Randomized Controlled Trial. (PubMed)

Intralesional Injection of the Measles-Mumps-Rubella Vaccine into Resistant Palmoplantar Warts: A Randomized Controlled Trial. Common resistant-to-therapy warts pose a challenge to both clinicians and patients. Among many destructive and immunotherapeutic options, no single, fully effective treatment has been suggested yet. Many investigations, including those using intralesional antigen administrations, have demonstrated that cellular immunity plays a major role in the clearance of human (...) papilloma virus (HPV) infection. The aim of the present study was to evaluate the effects of the intralesional injection of the measles-mumps-rubella (MMR) vaccine into resistant-to- treatment palmoplantar warts and its complications.In this single-blind, randomized, controlled clinical trial, 60 cases with resistant-to-therapy palmoplantar warts referring to the Dermatology Clinic of Bou-Ali Sina Hospital of Sari between June 2015 and 2016 were randomly assigned to 2 equal groups: the MMR Group

2019 Iranian journal of medical sciences

6. UK National Guidelines on the Management of Anogenital Warts

with or without coincidental benign warts. This includes intraepithelial neoplasia affecting the vulva (VIN), vagina (VaIN), perianal area (PAIN), anus (AIN) and penis (PIN). The diagnosis of intraepithelial neoplasia is made through histology. The presence of pigmentation, depigmentation, pruritus, underlying immune-deficiency, prior history of intraepithelial neoplasia on the same or distant anogenital sites, may raise suspicion of anogenital neoplasia. 6 Assessment of the patient with anogenital warts (...) ablative methods such as cryotherapy, excision, TCA or electrocautery 19 • Imiquimod is suitable treatment for both keratinised and non- keratinised warts. • People with a small number of low volume warts, irrespective of type, can be treated with ablative therapy or topical treatment with podophyllotoxin from the outset. • Podophyllotoxin or Imiquimod are suitable for home treatment by patients. The patient should be given a demonstration on lesion finding and treatment application. • Very large wart

2015 British Association for Sexual Health and HIV

7. Infrared Bioeffect System for the Treatment of Cutaneous Warts

followed by clearance of other distant lesions, a phenomenon suggesting that local hyperthermia could aid in establishing a specific immune response to eliminate HPV.So the purpose of the study is to evaluate the safety and efficacy of controllable infrared bioeffect system to treat cutaneous warts. This trial was designed into two groups, one was experimental group (thermal therapy group), the other one was control group (liquid nitrogen cryotherapy group). The ratio of participants was 1:1 (...) : No Criteria Inclusion Criteria : 18-70 years old signed informed consent clinical diagnosed HPV induced cutaneous warts no local or systemic therapy within 3 months effective contraception for 6 months after signed informed consent Exclusion Criteria: HbsAg(+), HCV-Ab(+), HIV-Ab(+) skin lesions associated with other infections pregnant or breast-feeding woman unsuitable to be treated by liquid nitrogen cryotherapy scar diathesis Contacts and Locations Go to Information from the National Library

2018 Clinical Trials

8. The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts

of the patients for treatment of warts. There are on two main therapeutic options: the first is the conventional destructive and aggressive method, which includes treatment with chemical cautery, cryo- therapy, electro cauterization, surgical excision, and laser ablation . This method depends on destruction of the area of epidermis infected with the virus. The recurrence rates after these therapy modalities maybe high. The second is the immunotherapy, which is based on the activation of the immune system (...) to deal with the virus and suppress its activity. Such therapy may be applied either topically or through intra- lesional injection or through systemic administration . Intra-lesional immunotherapy utilizes the ability of the immune system to mount a delayed-type hypersensitivity response to various antigens and also the wart tissue. This therapy has been found to be associated with the production of Th1 cytokines that activate cytotoxic and natural killer cells to eradicate HPV infection. This clears

2018 Clinical Trials

9. An aberrant reaction to Candida albicans antigen used for recalcitrant warts successfully treated with oral prednisone (PubMed)

101665210 2352-5126 CA, candida antigen immune therapy papillomavirus 2018 4 25 6 0 2018 4 25 6 0 2018 4 25 6 1 epublish 29687060 10.1016/j.jdcr.2018.01.010 S2352-5126(18)30019-5 PMC5909483 Br J Dermatol. 2011 Aug;165(2):233-46 21219294 J Drugs Dermatol. 2004 May-Jun;3(3):263-5 15176159 Cutis. 2002 Sep;70(3):185-92 12353895 Dermatitis. 2005 Dec;16(4):216; author reply 216-7 16536337 Dermatitis. 2005 Mar;16(1):38-40 15996350 J Pediatr Adolesc Gynecol. 2003 Oct;16(5):269-83 14597015 Clin Dermatol. 1997 (...) An aberrant reaction to Candida albicans antigen used for recalcitrant warts successfully treated with oral prednisone 29687060 2019 02 26 2352-5126 4 3 2018 Apr JAAD case reports JAAD Case Rep An aberrant reaction to Candida albicans antigen used for recalcitrant warts successfully treated with oral prednisone. 242-244 10.1016/j.jdcr.2018.01.010 La'Pelusa Andrew A Department of Dermatology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio. Rorex Jennifer J Department

Full Text available with Trip Pro

2018 JAAD Case Reports

10. Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.

. The secondary objective is to determine the tolerability of this new mode of administration of cidofovir in the pediatric population Condition or disease Intervention/treatment Phase Warts Drug: Cidofovir Phase 2 Detailed Description: This study includes pediatric patients with history of either primary or iatrogenic immune-suppression who are seeking treatment of warts that have already proven recalcitrant to standard therapy. The first cohort will include 4 patients ages 12 to 17. After all tests indicate (...) Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population. Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2015 Clinical Trials

11. Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients. (PubMed)

Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients. Infection with different species of cutaneous human papillomaviruses (cHPV) of genus alpha (cαHPVs) and associated skin disease are highly prevalent in solid organ transplant recipients (OTR), documenting the importance of the immunological control of HPV infection.To investigate the natural course of cαHPV (...) in humoral L1-specific immune responses during the course of iatrogenic immunosuppression, comparing median values 30 d before and 30 d after initiation of immunosuppressive therapy (p < 0.05). This difference disappeared after long-term (>1 year) immunosuppression. The predominant cellular L1-specific immune response was of type T(H)1 (CD4(+)CD40L(+)IL-2(+)IFN-γ(+)). Consistent with the detected L1-specific antibody titers, L1-specific T(H)1 responses were unchanged in long-term immunosuppressed OTR

2015 Journal of dermatological science

12. Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response

virus (HCV) or Hepatitis B virus (HBV) (Ag HBS) tests; Patients whose regular partner(s) have active uncontrolled clinical EGW; Patients who received the HPV Vaccine at any time before enrolment to the study; Any serious chronic or progressive disease according to the judgement of the investigator; Patients with history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system, or under immunosuppressive therapy including use of systemic corticosteroids (...) Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2017 Clinical Trials

13. A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

and Baseline Subjects free of any clinically significant dermatologic disorder in the treatment area Subjects free of any clinically significant systemic condition which will interfere with the study assessments or increase the risk of AEs Subjects willing to refrain from using other topical products in the treatment area, or prohibited medications for the duration of the study Exclusion Criteria: Subjects who have used any wart treatments/therapies, prescription or over-the-counter, as follows: Salicylic (...) ), imiquimod, 5-fluorouracil, bleomycin, podophyllin or any other wart immunotherapy or treatment (e.g., Candida antigen) designed to stimulate immune response within 12 weeks of the Baseline Visit. Female subjects who are pregnant, nursing/breastfeeding, or plan to become pregnant within the study period including the follow-up period. Subjects who are immunocompromised. Subjects who have taken, within 30 days prior to the Baseline visit, or require treatment with systemic immunosuppressive

2017 Clinical Trials

14. Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts

cytotoxic and natural killer cells to eradicate HPV infection. This clears not only the local warts but also distant warts unlike traditional wart therapies [ 11 ] . There are a few side effects reported by most of the studies. The most common side effect was pain and discomfort during injection, however, serious side effects such as vitiligo-like depigmentation and painful purple digit have also been reported [ 12 ] . Zinc is important for immune regulation as it stimulates the leucocytes and natural (...) immunity [ 2,3.]. However, warts can persist and increase in size and number [2] . Warts may reflect a localized or systemic cell-mediated immune (CMI) deficiency to HPV. Various reasons like lack of production of memory T cells to target HPV infection, failure of clonal expansion of lymphocytes to adequate stimulation, inability of T lymphocytes to traffic to sites of infection and weak effector response mechanism have been hypothesized. [4] .] Consequently, warts are particularly exuberant

2017 Clinical Trials

15. Clinical Study : Efficacy and Safety of Three Cryotherapy Devices for Wart Treatment

for Pixie® are in line with the indications presented in the collected literature data, as well as with the indications of equivalent devices. The benefits of warts treatment without the use of chemicals are clearly evidenced. The treatment period is much shorter (one treatment compared to daily application of keratinolytics or fluorouracil, over a period of a few weeks). The cryogen therapy application through a conic tip is much more precise than with chemical substances. Chemical substance (...) zone. Subject with a known allergy to one of the component of the products or to the comparator. Subject who has diabetes. Subject having problems with blood circulation, or having a blood clotting condition. Subject with immune deficiency or autoimmune disease. Subject presenting more than 10 warts on the body. Subject presenting bleeding warts. Subject presenting birthmarks, moles, warts with hairs growing from them, or any other spots. Subject having a sensitive skin, inflamed, infected

2017 Clinical Trials

16. Carbon Dioxide Laser and Cryotherapy in Treatment of Warts

). Despite the presence of several therapeutic options, treatment of warts can present a challenge and they are not uniformly effective. Viral warts often disappear without treatment. In case of pain, discomfort and long duration they can be treated . Treatment options include cryotherapy, electrocautery, salicylic acid, immune therapy, minor surgery or laser surgery. Common warts have a distinctive appearance and can usually be diagnosed with the unaided eye; however, early growth stages and post (...) , Adult, Older Adult Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients with common warts male or females any age. Patient is able to read and understand English and will give written informed consent to participate. Patient elects to undergo carbon dioxide laser therapy or cryotherapy for treatment of common warts. Warts to be treated will be located only on the hands. Exclusion Criteria: Non cooperative patients. Patients on other lines of treatment

2017 Clinical Trials

17. Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients

Papilloma Virus infection among women in the world ranges from 2% to 44%. The conventional modalities in treatment of warts include destructive therapies such as salicylic acid, trichloroacetic acid, cryotherapy, silver nitrate, phenol, cantharidin, surgical interventions and laser, antiproliferative agents such as bleomycin, vitamin D analogs, podophyllin, 5 fluorouracil and antiviral agents such as cidofovir and retinoids. There are different mechanisms have been proposed for the resolution of warts (...) Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2017 Clinical Trials

18. Safety and Efficacy of Immune Therapy for Condyloma

Safety and Efficacy of Immune Therapy for Condyloma Safety and Efficacy of Immune Therapy for Condyloma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of Immune Therapy for Condyloma (...) Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 80 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Outcomes Assessor) Primary Purpose: Treatment Official Title: Safety and Efficacy of Immune Therapy for Condyloma Actual Study Start Date : June 25, 2017 Estimated Primary Completion Date : December 31, 2018 Estimated Study Completion Date : June 30

2017 Clinical Trials

19. Wart Immune Therapy

Wart Immune Therapy Wart Immune Therapy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Wart Immune Therapy Wart Immune Therapy Aka (...) : Wart Immune Therapy , Intralesional Candida Injection From Related Chapters II. Indication s refractory to other treatments Not FDA approved (anecdotal support only) III. Preparation Killed Candida (Monilia albicans) Used in Manitou control (1:1000 solution) IV. Application Preparation Mix equal parts of 1% without Use 30 gauge needle Choose largest wart Injection Inject 0.1 cc to 0.3 cc intradermal beside wart Wart should blanche with injection V. Precautions Wear protective glasses Limit to 3

2015 FP Notebook

20. Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

) [ Time Frame: 24 Weeks ] Count of all visible lesions Clinical Assessment (Percent clearance of treated lesions) [ Time Frame: 24 Weeks ] Clinical Assessment (Reduction of wart size) [ Time Frame: 24 Weeks ] Includes 2D and 3D photography Clinical Assessment (PRO) [ Time Frame: 24 Weeks ] Change in Patient-reported outcomes Pharmacodynamics (Local Immunity Status) [ Time Frame: 24 Weeks ] Histological changes Pharmacodynamics (HPV Viral Load Assessment) [ Time Frame: 24 Weeks ] Quantitative PCR (...) to screening. Use of active treatment (i.e. cryotherapy, laser therapy, topical medication and/or surgical treatments) for genital warts within 28 days prior to first study drug administration. Immunosuppressed patients, having an immunodeficiency (primary or secondary, like HIV) or receiving immunosuppressive therapy (i.e. Transplant patients). Males or Females who received a vaccination with Gardasil or Cervarix. Any (medical) condition that would, in the opinion of the Investigator, potentially

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>